# Avalo Therapeutics to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-d5aa5d26
Ticker: AVTX
Company: Avalo Therapeutics
Source: Avalo Therapeutics
Published: 2026-09-03 11:00 EST
Original Source URL: https://ir.avalotx.com/news-events-presentations/press-releases/detail/231/avalo-therapeutics-to-participate-in-upcoming-investor-conferences
## Summary

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated…...

## Article Body
September 03, 2026 7:00am EDT

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Cantor Global Healthcare Conference 2026

Fireside Chat September 10, 2026, at 8:00 am ET

Morgan Stanley 24th Annual Global Healthcare Conference

1x1 meetings only September 16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Presentation September 16, 2026, at 8:30 am ET

Stifel 2026 Virtual Immunology and Inflammation Forum

Fireside Chat September 24, 2026, at 9:30 am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com .

For media and investor inquiries

Christopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com 410-803-6793

or

Meru Advisors Lauren Glaser lglaser@meruadvisors.com

Source: Avalo Therapeutics Released September 3, 2026
## Recent Company News
- 2026-09-04 20:05 EST — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2) — Source: Avalo Therapeutics
- 2026-09-03 11:00 EST — [Avalo Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-d5aa5d26) — Source: Avalo Therapeutics
- 2026-08-06 11:00 EST — [Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-reports-second-quarter-2026-financial-results-and-recent-busi-284a6cbe) — Source: Avalo Therapeutics
- 2026-07-22 11:00 EST — [Avalo Therapeutics to Participate in the BTIG Biotechnology Conference](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-btig-biotechnology-conference-399b4284) — Source: Avalo Therapeutics
- 2026-07-07 11:00 EST — [Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum-ef62dbcf) — Source: Avalo Therapeutics
## Related News
- 2026-09-09 23:25 EST — IRON — [Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-718b0075)
- 2026-09-09 20:17 EST — COO — [CooperCompanies Announces Third Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-third-quarter-2026-results-0256684b)
- 2026-09-09 20:15 EST — COO — [CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization](https://biopharmsignal.com/news/COO/coopercompanies-completes-strategic-review-increases-share-repurchase-authorizat-c3b7ff3b)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment](https://biopharmsignal.com/news/NBTX/nanobiotix-participera-la-conf-rence-h-c-wainwright-28th-annual-global-investmen-8b1208fb)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-co-bd8b771d)